Sona Nanotech Inc.

Equities

SONA

CA83541C1059

Medical Equipment, Supplies & Distribution

Market Closed - Canadian Securities Exchange Other stock markets 11:54:19 2024-04-25 am EDT			5-day change	1st Jan Change
0.42 ^CAD	0.00%		+13.51%	+75.00%

Apr. 12	Sona Nanotech Provides Interim Results of Dalhousie Study	MT
Apr. 12	Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study	CI

Sona Nanotech Inc. Reports Earnings Results for the Third Quarter Ended July 31, 2021

September 28, 2021 at 01:59 pm EDT

Sona Nanotech Inc. announced earnings results for the third quarter ended July 31, 2021. For the third quarter, the company announced net loss was CAD 2.187 million compared to CAD 1.718 million a year ago. Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.03 a year ago. For the nine months, net loss was CAD 8.993 million compared to CAD 2.874 million a year ago. Basic loss per share from continuing operations was CAD 0.14 compared to CAD 0.05 a year ago.

Latest news about Sona Nanotech Inc.

Sona Nanotech Provides Interim Results of Dalhousie Study	Apr. 12	MT
Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study	Apr. 12	CI
Sona Nanotech Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	Mar. 29	CI
Sona Nanotech Inc. Appoints Dr. Carman Giacomantonio to its Advisory Board	Mar. 18	CI
Sona Nanotech Inc. Announces Filing of Provisional Patent Application	Mar. 18	CI
Sona Nanotech Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	Feb. 27	CI
Sona Nanotech Inc. Announces Retirement of Michael Gross from the Board of Directors	Jan. 10	CI
Sona Nanotech Inc. announced that it has received CAD 0.75 million in funding	Nov. 26	CI
Sona Nanotech Inc. announced that it has received CAD 0.75 million in funding	Nov. 26	CI
Sona Nanotech Inc. announced that it expects to receive CAD 0.75 million in funding	23-10-17	CI
Sona Nanotech Inc. announced that it expects to receive CAD 0.75 million in funding	23-10-17	CI
Sona Nanotech Inc. Provides Corporate Update on Operating Activities	23-10-12	CI
Sona Nanotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-28	CI
Sona Nanotech Inc. Announces Innovative Research Initiative to Undertake with Giacomantonio Immuno-Oncology Research Group	23-09-11	CI
Sona Nanotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-28	CI
Sona Nanotech Inc. Announces First Territorial Patent Grant for Its Proprietary, Toxin-Free Gold Nanorod Manufacturing Process with A Registration in South Korea	23-05-18	CI
Sona Nanotech Inc. Announces Board Changes	23-05-18	CI
Sona Nanotech Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-30	CI
Sona Nanotech Inc. completed the acquisition of Siva Therapeutics Inc.	23-03-22	CI
Sona Nanotech Inc. Auditor Raises 'Going Concern' Doubt	23-02-26	CI
Sona Nanotech Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	23-02-26	CI
Sona Nanotech Inc. completed the acquisition of Siva Therapeutics, Inc.	23-02-26	CI
Sona Nanotech Inc. announced that it has received CAD 1.1 million in funding	23-02-23	CI
Sona Nanotech Inc. Receives Technology Assessment Results from NCL	23-02-08	CI
Sona Nanotech Inc. entered into a binding agreement to acquire Siva Therapeutics Inc. for $8.7 million.	23-01-25	CI

Chart Sona Nanotech Inc.

Duration

Period

More charts

Company Profile

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.

Sector

Medical Equipment, Supplies & Distribution

Calendar

01:00pm - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SONA NANOTECH INC.	+75.00%	30.4M
ABBOTT LABORATORIES	-2.92%	185B
MEDTRONIC PLC	-3.80%	105B
BECTON, DICKINSON AND COMPANY	-5.48%	66.59B
DEXCOM, INC.	+11.22%	54.66B
CENCORA, INC.	+16.74%	47.78B
HOYA CORPORATION	+4.06%	41.26B
WEST PHARMACEUTICAL SERVICES, INC.	+4.56%	26.95B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.64%	26.37B
TERUMO CORPORATION	+12.96%	24.8B

Other Medical Equipment, Supplies & Distribution